Trial Profile
A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 May 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Doxorubicin
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Apr 2016 Status changed from not yet recruiting to recruiting.
- 18 Feb 2015 New trial record